Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)
Completed
Conditions studied: Prenatal Exposure Delayed Effects, Multiple Sclerosis, Pregnancy
In brief
The primary objectives of the study were to prospectively record and analyze birth defects and spontaneous fetal losses in women with multiple sclerosis (MS) exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy, where the outcome of the pregnancy was unknown prospectively and to prospectively record and analyze pregnancy outcomes in an exploratory fashion of women with MS who stopped therapy, but who may have been exposed to Avonex with approximately 1 week of conception or during the first trimester of pregnancy.
Key facts
- Study ID
- NCT00168714
- Run by
- Biogen
- People needed
- 329
- Starts
- 2004-02-01
- Expected to finish
- 2011-09-01
- Last updated by the study team
- 2014-06-09
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Kendle — Wilmington, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.